These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7116342)
1. Management of patients who fail to respond to levodopa therapy. Duvoisin RC Clin Neuropharmacol; 1982; 5 Suppl 1():S13-8. PubMed ID: 7116342 [TBL] [Abstract][Full Text] [Related]
2. Levodopa with benserazide or carbidopa in Parkinson disease. Rinne UK; Mölsä P Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221 [TBL] [Abstract][Full Text] [Related]
3. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report. Savery F Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863 [No Abstract] [Full Text] [Related]
5. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. Hoehn MM Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419 [TBL] [Abstract][Full Text] [Related]
6. The effects of combining carbidopa with levodopa for Parkinson's disease. Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406 [No Abstract] [Full Text] [Related]
7. Management of motor side effects of chronic levodopa therapy. Jankovic J Clin Neuropharmacol; 1982; 5 Suppl 1():S19-28. PubMed ID: 7116343 [TBL] [Abstract][Full Text] [Related]
9. Psychiatric symptoms with initiation of carbidopa-levodopa treatment. Lin JT; Ziegler DK Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518 [TBL] [Abstract][Full Text] [Related]
10. [The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients]. Völler GW; Deze J ZFA (Stuttgart); 1976 Mar; 52(7):380-8. PubMed ID: 773025 [No Abstract] [Full Text] [Related]
11. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197 [TBL] [Abstract][Full Text] [Related]
12. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Rivera-Calimlim L; Tandon D; Anderson F; Joynt R Arch Neurol; 1977 Apr; 34(4):228-32. PubMed ID: 843257 [TBL] [Abstract][Full Text] [Related]
13. Treatment of "on-off effect" with a dopa decarboxylase inhibitor. Sweet RD; McDowell FH; Wasterlain CG; Stern PH Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214 [TBL] [Abstract][Full Text] [Related]
14. Levodopa-associated hemifacial dystonia. Mark MH; Sage JI Mov Disord; 1991; 6(4):383. PubMed ID: 1758464 [No Abstract] [Full Text] [Related]
15. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700 [TBL] [Abstract][Full Text] [Related]